Kirkham B W, Thien F, Pelton B K, Pitzalis C, Amlot P, Denman A M, Panayi G S
Rheumatology Unit, United Medical School, Guy's Hospital, London, UK.
J Rheumatol. 1992 Sep;19(9):1348-52.
Murine monoclonal antibody (Mab) therapy in patients with rheumatoid arthritis (RA) produces an antimouse immunoglobulin response by the recipient. We studied a chimeric (human/mouse) CD7 Mab, in a dose ranging tolerability study in 10 patients with RA. Modest improvements in disease activity occurred with frequent acute adverse effects of malaise, fever and nausea. After treatment, peripheral blood T lymphocyte numbers fell by 50% and CD7 expression fell by 97% for less than 7 days. Our study demonstrates chimeric Mab function in vivo and illustrates the influence of antibody isotype and patient characteristics on adverse effects.
类风湿关节炎（RA）患者接受鼠单克隆抗体（Mab）治疗会引发受体的抗小鼠免疫球蛋白反应。我们在10例RA患者中进行了一项剂量范围耐受性研究，研究一种嵌合（人/鼠）CD7单克隆抗体。疾病活动度有适度改善，但常伴有不适、发热和恶心等急性不良反应。治疗后，外周血T淋巴细胞数量下降50%，CD7表达下降97%，持续时间不到7天。我们的研究证明了嵌合单克隆抗体在体内的功能，并阐明了抗体同种型和患者特征对不良反应的影响。
